A phase I and pharmacological study of the matrix metalloproteinase inhibitor BB-3644 in patients with solid tumours.
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000631:Aminopyridines / Q000008:administration & dosage / Q000009:adverse effects* / Q000493:pharmacokinetics / Q000494:pharmacology*; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D006877:Hydroxamic Acids / Q000008:administration & dosage / Q000009:adverse effects* / Q000493:pharmacokinetics / Q000494:pharmacology*; D008297:Male; D020714:Maximum Tolerated Dose; D008666:Metalloendopeptidases; D008875:Middle Aged; D009140:Musculoskeletal Diseases / Q000139:chemically induced; D009369:Neoplasms / Q000188:drug therapy*; D016896:Treatment Outcome
D000631:Aminopyridines; C448637:BB 3644; D006877:Hydroxamic Acids; D008666:Metalloendopeptidases